| Literature DB >> 34093520 |
Cecilia Svanberg1, Rada Ellegård1, Elisa Crisci1, Mohammad Khalid1, Ninnie Borendal Wodlin2, Maria Svenvik3, Sofia Nyström1,4, Kenzie Birse5, Adam Burgener6, Esaki M Shankar7, Marie Larsson1.
Abstract
Genital mucosal transmission is the most common route of HIV spread. The initial responses triggered at the site of viral entry are reportedly affected by host factors, especially complement components present at the site, and this will have profound consequences on the outcome and pathogenesis of HIV infection. We studied the initial events associated with host-pathogen interactions by exposing cervical biopsies to free or complement-opsonized HIV. Opsonization resulted in higher rates of HIV acquisition/infection in mucosal tissues and emigrating dendritic cells. Transcriptomic and proteomic data showed a significantly more pathways and higher expression of genes and proteins associated with viral replication and pathways involved in different aspects of viral infection including interferon signaling, cytokine profile and dendritic cell maturation for the opsonized HIV. Moreover, the proteomics data indicate a general suppression by the HIV exposure. This clearly suggests that HIV opsonization alters the initial signaling pathways in the cervical mucosa in a manner that promotes viral establishment and infection. Our findings provide a foundation for further studies of the role these early HIV induced events play in HIV pathogenesis.Entities:
Keywords: HIV - human immunodeficiency virus; cervical tissue; complement opsonized HIV-1; innate immunity; primary infection; proteomics; transcriptomics
Year: 2021 PMID: 34093520 PMCID: PMC8173031 DOI: 10.3389/fimmu.2021.625649
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Model of HIV in vitro infection of cervical mucosal tissue. Cervical biopsies 3 mm2-8 mm2 cervical mucosal biopsies were spin-occulated with 250ng/ml opsonized referred to as free HIV-1 (F-HIV), complement-opsonized HIV-1 (C-HIV), complement and antibody opsonized HIV-1 (CI-HIV) or mock treatment for 2h. The tissues were thereafter washed and re-incubated, and then harvested after 6h, 24h, or 5 days. The mucosal tissues and emigrated mucosal cells were harvested and analyzed using RNA seq, proteomics, qPCR, and flow cytometry.
Figure 2Complement opsonization of HIV increases infection of emigrating DCs but decreases infection of emigrating T cells. Cervical mucosal tissues were exposed to 250ng/ml HIV-1 BaL that was either F-HIV, C-HIV, or CI-HIV or mock-treated and cultured for 24h or 4-5 days. (A) The HIV-1 exposed cervical mucosal tissues were lysed, and RNA purified and used for qPCR to measure HIV1 mRNA (gag). (B) The emigrating cells were collected day 4 or 5 and the cells stained for anti-CD3, anti-CD4, anti-CD1a/CD1c. The cells, DCs (CD1a+) and T helper cells (CD3+CD4+), were thereafter stained for HIV p24 gag and analyzed using flow cytometry for the level of HIV infection (p24+). (C) The supernatants from the HIV-1 exposed cervical mucosal tissues were harvested day 4or 5 and analyzed for HIV-1 p24 gag in an ELISA (N=21). *p < 0.05, **p < 0.01 and ***p < 0.001.
Figure 3Complement opsonization of HIV alters innate immune signaling and affects key inflammatory regulators in cervical mucosa. Cervical mucosal biopsies (3mm) were spin-occulated with 250ng/ml F-HIV, C-HIV; CI-HIV or mock for 2 hours. The biopsies were then washed and incubated for an additional 4h or 22h. The tissues and emigrated cells were harvested, and RNA was purified and whole transcriptome sequencing was performed. (A) Canonical pathways affected by the HIV exposure in the complete, i.e. endo and ecto, cervical tissue at 6h. (B) Canonical pathways affected by the HIV exposure in the ecto cervical tissue at 6h. (C) Analysis of expression log ratio of factors from the canonical pathway, “Dendritic Cell Maturation” identified in ectocervix tissue only. (D) Analysis of expression log ratio of factors from canonical pathway” NF-kB Signaling” identified in ectocervix tissue only. (E) Canonical pathways affected by the HIV exposure in the ectocervical tissue only at 24h. (N=6). Heat maps display pathways significantly affected by a treatment arm (p < 0.05) and activation z-scores are displayed.
Figure 4Upstream regulator analysis showing activation and upregulation of several genes induced by HIV in the cervical mucosal tissue 6h post exposure that is lost at 24h. Cervical mucosal biopsies (3mm) were spin-occulated with 250ng/ml F-HIV, C-HIV; CI-HIV or mock for 2 hours. The biopsies were then washed and incubated for an additional 4h or 22h. The tissues were harvested, and RNA was purified and whole transcriptome sequencing was performed. (A) Analysis of upstream regulators affected by the HIV exposure in the complete, i.e. endo and ecto, cervical tissue at 6h were assessed by IPA and presented as a heat map with the threshold for p-values set to log21.3 presented as an activation Z-score with a cutoff of 0.5 Z-score. (B) Analysis of upstream regulators affected by the HIV exposure in ectocervical tissue at 6h were assessed by IPA and presented as a heat map with the threshold for p-values set to log 1.3 presented as activation Z-score with a cutoff of 0.2 Z-score. (C) Analysis of upstream regulators affected by the HIV exposure in ectocervical tissue at 24h were assessed by IPA and presented as a heat map with the threshold for p-values set to log 1.3 presented as activation Z-score with a cutoff of 0.2 Z-score. (D) Analysis of expression log ratio of factors grouped as regulators of TNF from figure 4b. (N=6).
Figure 5Complement-opsonized HIV activates infection and viral replication pathways/groups in the ectocervical tissue. Cervical mucosal biopsies (3mm) were spin-occulated with 250ng/ml F-HIV, C-HIV; CI-HIV or mock for 2 hours. The biopsies were then washed and incubated for an additional 4h. The tissues were harvested, and RNA was purified and whole transcriptome sequencing was performed. Analysis of the RNA seq transcriptome was analyzed in the IPA using the Biofunctions and Diseases analysis for enrichment of groups/pathways involved in infection and viral replication and presented as a heat map with the threshold for p-values set to log 1.3 (p < 0.05) presented as activation Z-score. (N=6).
Proteins differentially abundant between viral treatment arms.
| Protein Name | Accession ID | Average FHIV | Average CHIV | Average CIHIV | Friedman p-value | General Function |
|---|---|---|---|---|---|---|
|
| CAN2_HUMAN | -0,031 | 0,092 | -0175 | 0,0001 | Regulation of cytoskeleton organization |
|
| FLOT2_HUMAN | -0,191 | 0,221 | 0,033 | 0,006 | Epidermal cell adhesion |
|
| PARP1_HUMAN | -0,074 | 0,148 | 0,091 | 0,007 | Transcription regulation |
|
| CYC_HUMAN | -0,324 | -0,323 | 0,022 | 0,008 | Cellular |
|
| STAM2_HUMAN | -0,078 | 0,456 | -0,017 | 0,01 | Protein transport |
|
| CNDP2_HUMAN | -0,165 | 0,045 | -0,186 | 0,01 | Proteolysis |
|
| RBMX_HUMAN | -0,102 | 0,111 | 0,075 | 0,013 | mRNA processing |
|
| THTR_HUMAN | -0,072 | 0,433 | -0,066 | 0,014 | rRNA transport |
|
| ERLN2_HUMAN | -0,004 | 0,203 | -0,04 | 0,014 | Lipid metabolism |
|
| H2AV_HUMAN | -0,288 | 0,165 | 0,042 | 0,016 | Chromatin organization |
|
| RAB35_HUMAN | 0,042 | 0,516 | 0,095 | 0,017 | Antigen processing and |
|
| MXRA7_HUMAN | 0,12 | 0,674 | 0,199 | 0,021 | Unknown |
|
| TLN2_HUMAN | 0,015 | 0,452 | 0,357 | 0,021 | Cell adhesion |
|
| SFPQ_HUMAN | 0,015 | 0,165 | 0,075 | 0,021 | Innate immunity |
|
| COMT_HUMAN | -0,01 | 0,247 | 0,053 | 0,021 | Catecholamine metabolism |
|
| E41L2_HUMAN | -0,048 | 0,226 | -0,009 | 0,021 | Cell cycle |
|
| NOP58_HUMAN | 0,189 | 0,42 | 0,02 | 0,021 | rRNA processing |
|
| BASI_HUMAN | -0,247 | 0,102 | -0,23 | 0,021 | ECM disassembly |
|
| H1X_HUMAN | -0,131 | 0,443 | 0,329 | 0,026 | Chromosome condensation |
|
| RAB5B_HUMAN | -0,097 | 0,43 | -0,065 | 0,027 | Antigen processing and |
|
| MYH9_HUMAN | -0,223 | -0,078 | 0,046 | 0,027 | Cell adhesion |
|
| NDRG1_HUMAN | -0,074 | 0,171 | -0,046 | 0,029 | Mast cell |
|
| PGRC1_HUMAN | 0,118 | 0,716 | 0,385 | 0,029 | Neutrophil degranulation |
|
| VP26A_HUMAN | -0,21 | 0,182 | 0,13 | 0,029 | Protein transport |
|
| RTN4_HUMAN | -0,145 | 0,409 | 0,171 | 0,03 | Neurogenesis |
|
| LYRIC_HUMAN | -0,052 | 0,375 | 0,084 | 0,033 | Positive regulation of NF-kappa B transcription |
|
| PTK_HUMAN | 0,068 | 0,301 | 0,194 | 0,033 | Cell adhesion |
|
| CROCC_HUMAN | 0,13 | 0,485 | 0,126 | 0,035 | Epithelial structure |
|
| NFIC_HUMAN | -0,199 | 0,228 | 0,083 | 0,035 | Transcription regulation |
|
| SPSY_HUMAN | -0,164 | 0,187 | 0,126 | 0,039 | Polyamine biosynthesis |
|
| K2C78_HUMAN | 0,053 | -0,107 | -0,449 | 0,039 | Keratinization |
|
| SBSN_HUMAN | -0,048 | 0,295 | -0,7 | 0,04 | |
|
| AL1A3_HUMAN | 0,001 | -0,298 | -0,019 | 0,041 | Retinoic acid metabolism |
|
| RBP2_HUMAN | -0,073 | 0,222 | -0,045 | 0,042 | mRNA transport |
|
| SYFA_HUMAN | -0,042 | 0,159 | 0,077 | 0,043 | Potein biosynthesis |
|
| CPNS1_HUMAN | -0,182 | -0,194 | -0,504 | 0,045 | ECM disassembly |
|
| ESYT1_HUMAN | -0,295 | 0,072 | -0,082 | 0,046 | Lipid transport |
|
| NID1_HUMAN | 0,002 | -0,006 | 0,234 | 0,047 | Cell adhesion |
|
| PININ_HUMAN | 0,034 | 0,129 | -0,057 | 0,049 | Cell adhesion |
|
| RL10A_HUMAN | -0,162 | 0,063 | 0,057 | 0,05 | Viral transcription |
Figure 6Free and complement-opsonized HIV exposure have diverse effects on expression of proteins involved in canonical pathways. Ecto-cervical biopsies were treated with F-HIV, C-HIV, CI-HIV, or mock treated for 24h. The samples were lysed and digested into peptides that was labeled with iTRAQ isobaric and analyzed using LC/MS. The resulting data were then normalized to the mock samples and (A) canonical pathways affected were analyzed by IPA and presented as a heat map with the threshold for p-values set to log 1.3 (p < 0.05) and presented as activation Z-score. (B) Venn diagram analysis was performed for the canonical pathways activated by F-HIV, C-HIV, CI-HIV to identify similarities in pathway activation. (N=5).
Biofunctions in F-HIV treated cervical mucosa tissue.
| Diseases or Functions Annotation | p-Value | Activation z-score | Molecules | # Molecules |
|---|---|---|---|---|
|
| 4.19E-02 | -0.849 | CAPNS1,CDH13,DNM1L,GRB2,PRDX4 | 5 |
|
| 3.28E-02 | 0.200 | DNM1L,GRB2,IGHA1,IGHA2,SERPINB9 | 5 |
|
| 4.15E-02 | 0.305 | CAPNS1,COX5A,DNM1L,GRB2,UBE2K | 5 |
|
| 1.84E-02 | 0.726 | AFG3L2,DNM1L,FGA,GRB2,GYG1,IGJ,MTX1,NHP2L1, | 11 |
|
| 2.74E-02 | 0.741 | CAPNS1,CCT5,CD99,COX5A,DNM1L,LGALS3BP,PRKA | 10 |
|
| 2.31E-02 | 1.087 | ALDH2,CAPNS1,CAPRIN1,CCT5,CD99,COX5A,DNM1L, | 15 |
|
| 6.21E-03 | 1.378 | AFG3L2,ALDH2,AP1G1,CAPNS1,CAPRIN1,CCT5,CD99, | 20 |
Proteomics data from cervical biopsies treated with F-HIV were normalized to the mock value for each donor and analyzed using. Ingenuity IPA (Qiagen) to determine the top biofunctions associated with this treatment.
Biofunctions in C-HIV treated cervical mucosa tissue.
| Diseases or Functions Annotation | p-value | Activationz-score | Molecules | # Molecules |
|---|---|---|---|---|
|
| 1.07E-02 | -1.964 | APOE,CKAP5,CUL2,DIABLO,FASN,MECP2,NUMA1,PRK | 10 |
|
| 1.19E-02 | -0.594 | CUL2,DIABLO,RAB35,YBX1 | 4 |
|
| 1.41E-02 | -0.366 | APOE,CASP14,CKAP5,CUL2,DDX19A,DIABLO,FASN,H2AFX,LAMA2,MECP2,NUMA1,PDXK,PPP3CA,PRKAR2B,PTMA,SCRIB,SUN1,YARS,YBX1 | 19 |
|
| 9.67E-03 | -0.222 | APOE,CASP14,CCT5,CKAP5,CUL2,DIABLO,FASN,H2AFX,PRKAR2B,PTMA,RAB35,YARS,YBX1 | 13 |
|
| 1.57E-03 | -0.152 | APOE,ASPH,CASP14,PITRM1,PREP,SPINK5 | 6 |
|
| 2.45E-03 | -0.152 | APOE,ASPHE,CASP14,CUL2,HGS,PITRM1,PREP,SPINK5 | 8 |
|
| 1.80E-03 | 0.640 | APOE,ASPH,CASP14,CKAP5,CUL2,HGS,PITRM1,PREP,SPINK5,UPF3B,YBX1 | 11 |
|
| 2.71E-04 | 1.067 | ANKFY1,APOE,ATP6VOD1,HGS,PPP3CA,RAB34,SCRIB | 7 |
|
| 3.07E-04 | 1.125 | APOE,ASPH,ASPSCR1,ATP6VOD1,CCT5,CES2,CUL2,DIABLO,FASN,H2AFX,HGS,LAMA2,MECP2,NCCRP1,NOP58,NUMA1,OSTF1,PDAP1,PDXK,PPP3CA,PREP,PRKAR2B,PTMA,RAB35,SCRIB,SF1,SRSF5,YARS,YBX1 | 29 |
|
| 2.40E-02 | 1.446 | ASPSCR1,CES2,NOP58,PRKAR2B,PTMA | 5 |
|
| 1.55E-02 | 1.951 | FASN,HGS,PRKAR2B,YBX1 | 4 |
|
| 2.64E-02 | 1.974 | APOE,DIABLO,H2AFX,LAMA2,MECP2,PPP3CA,PRKAR2B,SUN1 | 8 |
|
| 2.26E-02 | 2.597 | ANXA8/ANXA8L1,APOE,CKAP5,CROCC,FASN,LAMA2,MECP2,NSFL1C,NUMA1,PTK7,RAB35,YBX1 | 12 |
Proteomics data from cervical biopsies treated with F-HIV were normalized to the mock value for each donor and analysed using. Ingenuity IPA (Qiagen) to determine the top biofunctions associated with this treatment.
Biofunctions in CI-HIV treated cervical mucosa tissue.
| Diseases or Functions Annotation | p-value | Activation z-score | Molecules | #Molecules |
|---|---|---|---|---|
| Perinatal death | 3.29E-02 | -1.387 | CAPRIN1,CTNNA2,RAP1B,TOP2B,YBX1 CAPRIN1,COL5A1,CTNNA2,FOSL2,GPX3,HISTlH1C,M | 5 |
| Organismal death | 2.13E-03 | -1.201 | TAP,MUC5B,PRKACA,PTGES,RAP1B,RPL24,SF3B1,SRR T,TOP2B,YBX1 | 16 |
| Neonatal death | 3.92E-02 | -1.067 | CAPRIN1,CTNNA2,TOP2B,YBX1 | 4 |
| Proliferation of tumor celllines | 3.39E-02 | -0.432 | CES2,CLIP11,GKC,MTAP,PRKACA,PTGES,RAP1B,RPS14 ,YBX1 | 9 |
| Edema | 1.53E-02 | -0.277 | DBNL,PRKACA,PTGES,YBX1 | 4 |
| Growth Failure | 3.42E-02 | -0.277 | FOSL2,HIST1H1C,MUC5B,PRKACA,YBX1 ADD3,AG01,CAPRIN1,CASP14,CCT5,CTNNA2,CUL2,F | 5 |
| Cell death | 5.14E-03 | -0.255 | OSL2,HIST1H1C,IGKC,MUCSB,NAE1,PDCD5,PRKACA, PTGES,RAP1B,SRRT,TOP2B,YBX1 | 19 |
| Microtubule dynamics | 2.54E-03 | -0.176 | CAPRIN1,CDC42BPB,CLIP1,CTNNA2,DBNL,FLOTl,PRK ACA,RAP1B,TOP2B,YBX1 | 10 |
| Apoptosis | 3.14E-02 | -0.067 | AG01,CAPRIN1,CASP14,CUL2,HIST1H1C,MUC5B,NAE 1,PDCD5,PRKACA,PTGES,RAP1B,SRRT,TOP2B,YBX1 | 14 |
| Expression of RNA | 2.97E-02 | -0.014 | AG01,ALYREF,CAPRIN1,FOSL2,GCDH,HIST1H1C,NAE1 ,PRKACA,RPL24,RPS14,SRRT,YBX1 | 12 |
| Proliferation of cells | 2.48E-03 | 0.672 | AG01,CAPRIN1,CCT5,CDC42BPB,CES2,CLIP1,CMA1,C UL2,FLOTl,FOSL2,GPX3,1GKC,MTAP,NAE1,PRKACA,P TGES,RAP1B,RPS14,SRRT,TOP2B,YBX1 | 21 |
| Replication of Influenza A virus | 8.44E-03 | 1.131 | CDC42BPB,PRKACA,RPS14,SF3B1 | 4 |
| HIV infection | 1.23E-03 | 1.212 | COL5A1,MUC5B,RAP1B,SF3B1,SRRT,TM9SF2T, OP2B, YBX1 | 8 |
| Infection by HIV-1 | 2.35E-03 | 1.212 | COL5A1,MUC5B,RAP1B,SF3B1,SRRT,TM9SF2,YBX1 | 7 |
| Infection of cells | 1.07E-02 | 1.212 | COL5A1,MUC5B,RAP1B,SF3B1,SRRT,TM9SF2,YBX1 | 7 |
| Size of body | 4.69E-02 | 1.706 | DBNL,HIST1H1C,PRKACA,PTGES,RAP1B,TOP2B | 6 |
| Replication of RNA virus | 6.20E-04 | 1.964 | AG01,CDC42BPB,IGKC,PRKACA,RPS14,SF3B1,YBX1 | 7 |
| Proliferation of fibroblasts | 1.58E-02 | 1.969 | FOSL2,PTGES,RAP1B,YBX1 | 4 |
| Infection of embryonic cell lines | 6.71E-03 | 2.000 | COL5A1,SF3B1,SRRT,YBX1 | 4 |
| Infection of epithelial cell lines | 6.71E-03 | 2.000 | COL5A1,SF3B1,SRRT,YBX1 | 4 |
| Infection of kidney cell lines | 7.62E-03 | 2.000 | COL5A1,SF3B1,SRRT,YBX1 | 4 |
| AG01,CDC42BPB,COL5A1,HIST1H1C,IGKC,MTX1,MU | ||||
| Viral Infection | 1.84E-05 | 2.094 | C5B,PRKACA,RAP1B,RPS13,RPS14,SF3B1,SRRT,TM9S F2 TOP2B YBX1 | 16 |
Proteomics data from cervical biopsies treated with F-HIV were normalized to the mock value for each donor and analyzed using Ingenuity IPA (Qiagen) to determine the top biofunctions associated with this treatment.
Figure 7Proteins associated with viral infection is upregulated in cervical mucosa exposed to complement-opsonized HIV. Ectocervical biopsies treated with F-HIV, C-HIV, CI-HIV, or mock treated for 24h.The samples were lysed and digested into peptides that was labeled with iTRAQ isobaric and run on LC/MS. The resulting data were then normalized to the mock samples. (A) Affected proteins was thereafter analyzed in the IPA function “Diseases and Biological Functions” for visualization of enrichment of groups/pathways involved in infection and viral replication and presented as a heat map with the threshold for p-values set to log 1.3 (p<0.05) presented as activation Z-score. (B) Analysis of protein log ratio of factors involved in the “Diseases” pathway viral infection from figure 7A. (C) Analysis of protein log ratio of factors involved in the “Diseases” pathway Infection of cells from figure 7A. (D) Analysis of protein log ratio of factors involved in the “Diseases” pathway Organization of cytoplasmic molecules from figure 7A. (N= 6).